Natsumi Kawasaki

Toon, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti-CD20/CD3 Bispecific Antibody in a Syngeneic B-Cell Malignancy Mouse Model.

Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti-CD20/CD3 Bispecific Antibody in a Syngeneic B-Cell Malignancy Mouse Model.

Journal: EJHaem

Published: March 30, 2026

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy.

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy.

Journal: Frontiers in immunology

Published: November 29, 2025

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models.

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models.

Journal: EJHaem

Published: August 01, 2025

Bystander CAR-CD8+ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody.

Bystander CAR-CD8+ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody.

Journal: Journal for immunotherapy of cancer

Published: June 11, 2025

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.

Journal: EJHaem

Published: May 03, 2025

Development of Experimental Models of Antithrombin-independent Heparin Resistance Using Platelet Factor 4 and the Effect of Antithrombin in These Models.

Development of Experimental Models of Antithrombin-independent Heparin Resistance Using Platelet Factor 4 and the Effect of Antithrombin in These Models.

Journal: Journal of cardiothoracic and vascular anesthesia

Published: March 13, 2025

Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.

Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.

Journal: Leukemia & lymphoma

Published: August 07, 2023

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.

Journal: British journal of haematology

Published: April 19, 2022

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.

Journal: Molecular biology reports

Published: September 22, 2021

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.

Journal: International journal of hematology

Published: September 06, 2021

Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.

Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.

Journal: Molecular cancer therapeutics

Published: October 08, 2020

Long noncoding RNA NORAD regulates transforming growth factor-β signaling and epithelial-to-mesenchymal transition-like phenotype.

Long noncoding RNA NORAD regulates transforming growth factor-β signaling and epithelial-to-mesenchymal transition-like phenotype.

Journal: Cancer science

Published: February 02, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026